rabeprazole sodium
Pre-clinicalCompleted 1 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Refractory Reflux Esophagitis
Conditions
Refractory Reflux Esophagitis
Trial Timeline
Jan 1, 2011 → Aug 1, 2013
NCT ID
NCT01321567About rabeprazole sodium
rabeprazole sodium is a pre-clinical stage product being developed by Eisai for Refractory Reflux Esophagitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01321567. Target conditions include Refractory Reflux Esophagitis.
What happened to similar drugs?
3 of 20 similar drugs in Refractory Reflux Esophagitis were approved
Approved (3) Terminated (1) Active (16)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01264822 | Pre-clinical | Completed |
| NCT01321567 | Pre-clinical | Completed |
| NCT00855361 | Phase 1 | Completed |
| NCT00747695 | Phase 1 | Completed |
| NCT01286194 | Pre-clinical | Completed |
| NCT00236184 | Phase 3 | Completed |
| NCT00132496 | Phase 2 | Completed |
Competing Products
20 competing products in Refractory Reflux Esophagitis